United States 
Canada
EU
UKWe’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Tracey Jason, PhD, Head of Medical Affairs at Amylyx Pharmaceuticals Canada
Published: Canadian Neurological Sciences Federation (CNSF)
Date: June 26, 2022
Determining Individual Substantial Response in Amyotrophic Lateral Sclerosis: Utilizing a New Method on CENTAUR Trial Results
Lead Author: Lahar Mehta, MD, Head of Global Clinical Development at Amylyx Pharmaceuticals
Published: European Network to Cure ALS (ENCALS)
Date: June 2, 2022
Effect of Sodium Phenylbutyrate/Taurursodiol on Tracheostomy/Ventilation-Free Survival and Hospitalisation in Amyotrophic Lateral Sclerosis: Long-Term Results from the CENTAUR Trial
Lead Author: Sabrina Paganoni, MD, PhD
Published: Journal of Neurology, Neurosurgery and Psychiatry
Date: May 16, 2022
Survival Analyses from the CENTAUR Trial in Amyotrophic Lateral Sclerosis: Evaluating the Impact of Treatment Crossover on Outcomes
Lead Author: Sabrina Paganoni, MD, PhD
Published: Muscle & Nerve
Date: May 4, 2022
Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis and Alzheimer's Disease: Integrated Clinical Trial Experience
Lead Author: Steven E. Arnold, MD
Published: American Academy of Neurology (AAN)
Date: April 4, 2022
Expanded Access to Sodium Phenylbutyrate/Taurursodiol Coformulation in Amyotrophic Lateral Sclerosis: Learnings From an ALS Community Partnership
Lead Author: Machelle Manuel, PhD, Head of Global Medical Affairs at Amylyx Pharmaceuticals
Published: Muscular Dystrophy Association (MDA)
Date: March 13 - 16, 2022
Global Phase 3, Randomized, Placebo-Controlled Trial of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis (A35- 004 PHOENIX): Study Design Overview
Lead Author: Leonard H. van den Berg, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 8, 2021
Long-Term Functional Benefits and Safety of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: International Symposium on ALS-MND (MNDA)
Date: December 7, 2021
Safety and Biological Activity of a Fixed-Dose Coformulation of Sodium Phenylbutyrate and Taurursodiol (PB/TURSO) for the Treatment of Alzheimer's Disease: Results from the Phase 2a PEGASUS Study
Lead Author: Steven E. Arnold, MD
Published: Clinical Trials on Alzheimer’s Disease (CTAD)
Date: November 9 - 12, 2021
Longer Overall Survival in the CENTAUR Trial: A Rank-Preserving Structural Failure Time Model Adjusts for Crossover From Placebo to Sodium Phenylbutyrate (PB)/Taurursodiol (TURSO)
Lead Author: Sabrina Paganoni, MD, PhD
Published: Northeast ALS Consortium Annual Meeting (NEALS)
Date: October 7, 2021